SELLAS Life Sciences Group ( (SLS) ) has issued an announcement.

- REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - ...

Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - - Overall Response Rate (ORR) of 56% Achieved to ...

SELLAS Life Sciences Group has announced positive data from preclinical studies identifying the ASXL1 mutation as a ...

Cantor Fitzgerald has recently initiated Sellas Life Sciences Group Inc (SLS) stock to Overweight rating, as announced on July 21, 2021, according to Finviz. Earlier, on November 1, 2018, Oppenheimer ...

Cantor Fitzgerald has recently initiated Sellas Life Sciences Group Inc (SLS) stock to Overweight rating, as announced on July 21, 2021, according to Finviz. Earlier, on November 1, 2018, Oppenheimer ...

Based on elucidated biology of ASXL1 mutations, results from SELLAS’ clinical trials in acute myeloid leukemia (AML), and reports of common occurrence of ASXL1 mutations in some solid cancers ...

2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg BIW Median OS Not Reached - NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASD - GPS Currently ...

(RTTNews) - Sellas Life Sciences Group, Inc. (SLS), Wednesday announced positive data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective CDK9 ...

Based on elucidated biology of ASXL1 mutations, results from SELLAS’ clinical trials in acute myeloid leukemia (AML), and reports of common occurrence of ASXL1 mutations in some solid cancers, the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...